References
- Westhovens RDequeker J 2000. Rheumatoid arthritis and osteoporosis. Z Rheumatol 59 (7):33–8. doi:10.1007/s003930070036.
- Mirza F, Canalis E. Secondary osteoporosis: pathophysiology and management. Eur Journal endocrinology/European Fed Endocr Societies. 2015;173(3):R131–R51.
- Zerbini C, Clark PMendez-Sanchez L, Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. 2017;28(2):429–46.
- Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res Ther. 1999;2(1):33.
- Hans D, Goertzen AL, Krieg MA, et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the manitoba study. J Bone Miner Res. 2011;26(11):2762–2769.
- Muschitz C, Kocijan R, Haschka J, et al. TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone. 2015;79:259–266.
- Kužma M, Hans DKoller T, et al. Less strict intervention thresholds for the FRAX and TBS-adjusted FRAX predict clinical fractures in osteopenic postmenopausal women with no prior fractures. J Bone Miner Metab. 2017;1–9. https://doi.org/10.1007/s00774-017-0864–1
- Bréban S, Briot K, Kolta S, et al. Identification of rheumatoid arthritis patients with vertebral fractures using bone mineral density and trabecular bone score. J Clin Densitom. 2012;15(3):260–266.
- Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
- Heinlen LHumphrey M 2017. Skeletal complications of rheumatoid arthritis. Osteoporos Int 28 (10):2801–2812. doi:10.1007/s00198-017-4170-5.
- Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the oslo county rheumatoid arthritis register. Arthritis Rheum. 2000;43(3):522–530.
- Gough AK, Emery P, Holder R, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 1994;344(8914):23–27.
- Fardellone P, Séjourné APaccou J. Bone remodelling markers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:484280.
- Haugeberg G, Ørstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opt Rheumatol. 2003;15(4):469–475.
- Vis M, Wolbink G, Lodder M, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum. 2003;48(10):2996–2997.
- Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology. 2005;44(12):1546–1548.
- Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti‐tnf‐α therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069(1):420–427.
- Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheu Dis. 2010;69(5):872–875.